Spherically agglomerated solid dispersions of valsartan to improve solubility, dissolution rate and micromeritic properties
Keywords:
Valsartan, Spherical agglomeration, Solid dispersion, Solubility, Dissolution rate, Micromeritic propertiesAbstract
The objective of the present work was to enhance the solubility and dissolution rate of valsartan (VAL) a poorly water soluble antihypertensive, by spherically agglomerated solid dispersions using methanol, water and dichloromethane as good solvent, poor solvent and bridging liquid, respectively. The hydrophilic polymers like polyvinyl pyrrolidone, Hydroxypropyl β-cyclodextrin, Hydroxypropyl methylcellulose were used in agglomeration process. The pure drug (VAL) and its agglomerates with different polymers were characterize by differential scanning calorimetry (DSC), X-ray diffraction (XRD), IR spectroscopic studies and scanning electron microscopy (SEM). The DSC results indicated that decrease in melting enthalpy related to disorder in the crystalline content. XRD studies also showed changes in crystallanity, IR spectroscopy revealed that there were no chemical changes in the recrystallized agglomerates. The spherically agglomerated solid dispersions with different polymers exhibited marked increase in solubility, dissolution rate and micromeritic properties (bulk density, flow property, compactability) compared with VAL. The SEM studies showed that the agglomerates posseeses a good spherical shape.
References
Dhirendra K, Lewis
dispersions: a review. Pak J Pharm Sci 2009; 22:
-246.
Vasconcelos T, Sarmento B, Costa P. Solid
dispersion as strategy to improve oral
bioavailability of poor water soluble drugs. Drug
Disc Toady 2007; 12: 1068-1075.
Sharma DK, Joshi SB. Solubility enhancement
strategies for poorly water-soluble drugs in solid
dispersions: a review. Asian J Pharm 2007; 1: 9-
Gupta VR, Mutalik S, Patel MM, Jani GK.
Spherical crystals of celecoxib to improve
solubility, dissolution rate and micromeritic
properties. Acta Pharm 2007; 57: 173-184.
Usha AN, Mutalik S, Reddy MS, Rajith AK,
Kushtagi P, Udupa N. Preparation and, in vitro,
preclinical
spherical agglomerates. Eur J Pharm Biopharm
; 70: 674-683.
Yadav AV, Yadav VB. Designing of
pharmaceuticals to improve physicochemical
properties by spherical crystallization technique, J
Pharm Res 2008; 1: 105-112.
Kawashima Y, Cui F, Takeuchi H, Niwa T, Hino
T, Kiuchi K. Improvements in flowability and
compressibility of pharmaceutical crystals for
direct tabletting by spherical crystallization with a
two solvent system, Powder Technol 1994; 78:
-157.
Bodmeier R, Paeratakul R. Spherical
agglomerates of water-insoluble drugs, J Pharm
Sci 1989; 78: 964-967.
Di Martino P, Barthelemy C, Piva F, Joiris E,
Palmieri GF, Martelli S. Improved dissolution
behavior of fenbufen by spherical crystallization,
Drug Dev Ind Pharm 1999; 25: 1073-1081.
Sano A, Kuriki T, Kawashima Y, Takeuchi H,
Hino T, Niwa T. Par
spherical crystallization technique. V.
Improvement of dissolution and bioavailability of
direct compressed tablets prepared using
tolbutamide agglomerated cry m 1
Bull 1992; 40: 3030-3035.
Cui F, Yang M, Jiang Y, Cun D, Lin W, Fan Y,
Kawashima Y. Design of sustained-release
nitrendipine microspheres having solid dispersion
structure by quasi-emulsion solvent diffusion
method, J
Kawashima Y. Development of spherical
crystallization technique and its application to
pharmaceutical system,
-151.
Hu R, Zhu J, Chen G, Sun Y, Mei K, Li S.
Preparation of sustained-release simvastatin
microspheres by the spherical crystalliz
technique, Asian J Pharm Sci 2006; 1: 47-52.
Yang M, Cui F, You B, Fan Y, Wang L, Yue P,
Yang H. Preparation of sustained-release
nitrendipine microspheres with Eudragit RS and
Aerosil using quasi-emulsion solvent diffusion
method, Int J Pharm 2003; 259: 103-113.
Criscione L, Gasparo M
Whitebread S, Ramjoue HP, Wood JM.
Pharmacological profile of valsartan: a potent,
orally active, nonpeptide antagonist of the
angiotensin II AT1-receptor subtype, Br J
Pharmacol 1993; 110: 761-771.
Dina R, Jafari M. Angiotensin II receptor
antagonists: an overview, Am J Health Syst
Pharm 2000; 57: 1231-1241.
Lobenberg
bioavailability, bioequivalence and
biopharmaceutics classification system: new
scientific approaches to international regulatory
standards. Eur J Pharm Biopharm 2000; 50: 3-12.
Brunella C, Clelia DM, Ma
Improvement of solubility and stability of
valsartan by hydroxypropyl-beta-cyclodextrin. J
Incl Phenom Macrocycl Chem
Wells J. Pharmaceutical preformulation, the
physicochemical properties of drug substances.
In: M.E. Aulton (ed.), Pharmaceutics- the science
of dosage form design. 2nd ed. Churchill Livingst
M
In
pL2SooDU
methods for drug products Website. Available at:
http://www.accessdata.fda.gov/scripts/cder/dissol
ution/dsp_SearchResultsDissolutions.cfm?PrintAl
l=1. Accessed November 7, 2009.
Khan KA. The concept of dissolution efficiency.
J. Pharm Pharmacol 1975; 27:48-49.
Anderson NH, Bauer M, Boussac N, Khan-Malek
R, Munden P, Sardaro M. An evaluation of fit
factors and dissolution efficiency for the
comparison of in vitro dissoluti
Pharm Biomed Anal 1998; 17:811–822.
Huang HH, Huang C. Preparation of solid
coprecipitates of amorphous valsartan, US Patent
US 20070166372A1, 2007.
Rukhman I, Flyaks
Polymorphs of valsartan. US Patent US
B2,
